Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Thursday, October 22, 2026

⚡ Executive Takeaway

Wednesday was owners deciding the public market has stopped paying for breadth. Abbott, the most diversified name in large cap medtech, chose to hand Nutrition its own ticker. EQT and two of the longest duration investors on earth decided QIAGEN is worth 40 percent more outside the public market than inside it. Integer's holders voted the same conclusion on KKR's offer, and all of it lands one week after Medtronic finished carving out MiniMed. Each is a different owner reading the same signal: conglomerate cash flows are being discounted, and focus, or privacy, closes the gap. Notice who did not need the lesson. Danaher, which spent a decade splitting itself into sharper pieces, raised its year and was paid for it the same morning Abbott's in line quarter plus a fourteen month spin promise cleared lower. The market is not rewarding announced structure; it rewards structure delivered and uncertainty removed. For an executive holding a lagging division, Wednesday's message is blunt: the discount is now visible enough that private capital will do the separation for you, at a premium your shareholders only collect if you sell.

The split in one table, the QIAGEN terms, the CLARITY data, and the day's movers, all below. 👉 Read Full Analysis

🏥 Abbott Splits in Two

Abbott will spin off its $8.5 billion Nutrition business into an independent public company by the end of 2027, and the rest of a solid quarter traded like a footnote. ABT

The separation, announced at 7:25 am Eastern before the Q3 print, distributes shares of the new company to Abbott holders in a transaction intended to be tax free, pending a Form 10 and final board approval, per the release. Daniel Salvadori, who runs Established Pharmaceuticals and Nutrition today, becomes the new company's chief executive, and the combined dividend is pledged to equal Abbott's at separation. The quarter itself: sales of $13.0 billion grew 7.0 percent on a comparable basis, adjusted earnings rose 9.2 percent to $1.42 per share, and Abbott reaffirmed the midpoint of full year guidance while tightening the range to $5.50 to $5.55; GAAP earnings fell 43.6 percent on specified items including roughly $670 million of legal settlements. Inside devices, continuous glucose monitor sales grew 7.7 percent comparable, a deceleration worth watching with MiniMed now a standalone competitor. The market graded the package down 1.9 percent, our arithmetic. What separates:

🔬 Diagnostics Goes Private

An EQT led consortium will take QIAGEN private at €46.50 per share in cash, about €10.8 billion in enterprise value, the largest diagnostics take private of this cycle. QGEN

The offer, unanimously supported by QIAGEN's boards and announced after Wednesday's close, carries a 40.3 percent premium to the July 8 undisturbed price and 46.9 percent to the three month average before takeover reports surfaced, per the release, with Abu Dhabi Investment Authority and CPP Investments co investing alongside EQT's eleventh fund. Minimum acceptance is 50 percent plus one share, closing is expected mid 2027, and the Frankfurt and New York listings would be terminated after the post closing steps. QIAGEN separately reported preliminary Q3 sales of $548 million with adjusted earnings of $0.65 per share and suspended its full year outlook while the offer is pending. The stock closed at $50.00, up 2.2 percent, before the announcement, so Thursday is the first reaction session. Count what is leaving the public diagnostics shelf this month alone: Exact Sciences is inside Abbott, BioReference is going to Labcorp, and QIAGEN now has a dated path out entirely.

👁 Uveitis Phase 3s

Brepocitinib swept both Phase 3 trials in non infectious uveitis, cutting the risk of treatment failure by roughly three quarters, and a second indication filing is planned for the first half of 2027. ROIV

In CLARITY-1 and CLARITY-2, every patient tapered off steroids entirely by week eight and then had to hold remission on study drug or placebo alone. On brepocitinib 45 mg once daily, the hazard ratios for treatment failure were 0.27 and 0.22, both p<0.0001, with week 48 failure rates of 35.4 versus 78.7 percent and 32.4 versus 77.8 percent, per Priovant's release. Pooled across the trials, 62 percent of patients reached steroid free quiescence in both eyes versus 20 percent on placebo, and macular edema resolved in 42 percent versus 4.8 percent. Three percent discontinued for adverse events, with no new safety signals reported. The drug is already approved in dermatomyositis as LISRAYA, so the planned uveitis sNDA would make this a two indication franchise within roughly a year of launch. Roivant closed up 5.4 percent, our arithmetic.

💰 Capital Markets

Arcus sold $250 million of stock at $17.50, about a quarter below where the shares traded the day after its kidney cancer data. RCUS | TKNO | IAM | ETRA

The offering launched minutes after a session in which Arcus fell 19.6 percent with no company disclosure we could find, then priced overnight at $17.50: 8.4 percent below Wednesday's close and 26.3 percent below Tuesday's post data close, our arithmetic, with closing expected Friday. Elsewhere the window kept repricing. Teknova's first session after its $40 million offering cleared 20.8 percent lower. Iambic posted its first close below its $16.00 offer price, at $15.80, a week after trading 48.8 percent above offer. Electra's overallotment clock has run past its roughly October 21 expiry with no exercise announcement we could find in Wednesday night searches. And reverse mergers are running at their highest level since 2021 as PIPEs flood the market, per a report covered by Fierce Biotech. The pattern is consistent: positive data no longer buys premium capital, it buys access to capital at a discount.

📟 The Earnings Tape

Danaher raised its year and was paid for it; Medpace grew awards double digits and approved a $1 billion buyback after the close. DHR | MEDP

Danaher's Q3 revenue of $6.55 billion grew 8.5 percent reported and 3.0 percent core, 5.5 percent core excluding the fading respiratory franchise, and full year adjusted EPS guidance moved up to $8.57 to $8.62 from $8.45 to $8.60, per the release; the stock closed up 4.3 percent, our arithmetic. Medpace, reporting at 4:15 pm Eastern, grew revenue 8.5 percent to $716.0 million with net new awards up 10.6 percent to $873.4 million and backlog of $3.17 billion, and its board replaced the remaining $527 million repurchase authorization with a new $1.0 billion program through 2028. Thursday's 9:00 am call and session are the first reaction; Wednesday's 6.4 percent rise preceded the release, cause unassigned. For a CRO tape that spent the year under demand questions, awards growing faster than revenue is the number that matters.

🧪 First Reactions

The sessions after Tuesday evening's tape graded sell the news nearly across the board. GSK | IONS | ISRG | TLX

GSK's first session after the Hibsago approval closed down 1.2 percent, with partner Ionis down 2.5 percent, and Fierce Biotech separately reported GSK has quietly scrapped a trial of a next generation hepatitis B therapy, consolidating the franchise bet on the approved drug. Intuitive gave back 2.3 percent in its first session after the antitrust charge quarter. Telix fell 10.1 percent in its first session after a quarter up 19 percent from a year ago but down 1 percent sequentially. Alcon absorbed the Neurotech acquisition nearly flat at down 0.6 percent, HUTCHMED's license closing graded down 2.5 percent, and Disc closed at $76.00, 4.4 percent lower but a dollar above its $75.00 offer price the day before the deal closes, our arithmetic throughout. All are first reaction sessions and labeled as such.

📋 Quick Hits

👀 What To Watch Today

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

© 2026 BioMed Nexus. All rights reserved.